The year 2026 has finally brought the power of single-cell multi-omics into routine clinical research, allowing scientists to see the link between a cell's surface markers and its internal genetic activity simultaneously. A leading highlight in the cell surface markers market is the adoption of "CITE-seq" and similar technologies that use oligonucleotide-labeled antibodies to bridge the gap...